1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017

The radiopharmaceuticals market in the Asia-Pacific region was valued at $500.8 million in 2012; it is poised to reach $824.9million in 2017 at a CAGR of 10.5%.

The market is broadly classified into two segments, namely, diagnostic and therapeutic; the former dominated with about 80.7% share in 2012. Radioisotopes in the diagnostic market are categorized as SPECT and PET. Technetium 99m (Tc-99m) dominated the SPECT radioisotope market in 2012, followed by thallium-201(Tl-201), gallium-67 (Ga-67), and iodine-123 (I-123). SPECT is majorly used in cardiology-related diagnosis; it is poised to grow at a CAGR of 10.2% from 2012 to 2017. The PET radioisotopes market is dominated by fluoride-18 (F-18), followed by rubidium-82 (Rb-82).

Segments in the therapeutic market are beta emitters, brachytherapy isotopes, and alpha emitters. Quantitative information about alpha emitters has not been arrived at, as they have not been commercialized; recent clinical studies have, however, showcased immense potential of alpha isotopes in therapies. Beta emitters contribute the highest to the therapy market, dominated by iodine-131(I-131), which is poised to grow at a CAGR of 7.7% from 2012 to 2017. The Asia-Pacific market is driven by its applications for thyroid cancer, hyperthyroidism, and non-Hodgkin's lymphoma. Significant isotopes in the brachytherapy market are cesium-131(Cs-131), iodine-125 (I-125), palladium-103 (Pd-103), and iridium-192 (Ir-192).

Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are boosting the growth of the Asia-Pacific nuclear medicine market. Upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The nuclear disaster at Fukushima nuclear plants in 2011 had a major impact on radioisotope production in Japan, which is the largest consumer market in the Asia-Pacific region. The Asia-Pacific region is insulated from the global crisis in Mo-99 supply since the production is based on local nuclear plants and OPAL reactor of ANSTO. ANSTO is deemed as the future solution to compensate global Mo-99 demand.

Major players in the radiopharmaceuticals market are Nihon Medi-Physics Co., Ltd. (Japan), Covidien PLC (U.S.), Fujifilm Corporation (Japan), ANSTO (Australia), and IBA S.A (Belgium).

The Asia-Pacific stable isotopes market is dominated by deuterium (D2), oxygen-18 (O-18), carbon-13 (C-13), and nitrogen-15 (N-15). Research, pharmaceuticals, diagnostic and therapy, and industries are major applications. The Asia-Pacific stable isotopes market was estimated at $56.1 million in 2012 and is expected to cross $100.0 million by 2017 at a CAGR of 12.6%.

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) (U.S.) and Sigma Aldrich (U.S.) in 2012.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (Japan, China, India, South Korea, Malaysia, Indonesia, Australia, New Zealand, and Rest of Asia) to provide in-depth information on the Asia-Pacific scenario.

Asia-Pacific Radiopharmaceuticals Market

Diagnostic
SPECT
Tc-99m
Tl-201
Ga-67
I-123
Others
PET
F-18
Rb-82
Others
Therapy
Beta emitters
I-131
Sm-153
Re-186
Y-90
Lu-177
Others
Alpha emitters
Brachytherapy
Cs-131
I-125
Pd-103
Ir-192
Others

Asia-Pacific Enriched Stable Isotopes Market

Deuterium
Oxygen-18
Carbon-13
Nitrogen-15
Others

Radiopharmaceutical and Stable Isotope Markets, By Country

Japan
China
India
South Korea
Malaysia
Indonesia
Australia
New Zealand
Rest of Asia

Table Of Contents

Asia-Pacific Nuclear Medicine/Radiopharmaceuticals and Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] and (Deuterium, C-13) - Forecast to 2017
1 INTRODUCTION 27

1.1 KEY TAKE-AWAYS 27
1.2 REPORT DESCRIPTION 27
1.3 MARKETS COVERED 29
1.4 STAKEHOLDERS 31
1.5 RESEARCH METHODOLOGY 31
1.5.1 MARKET SIZE 31
1.5.2 MARKET SHARE 32
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 32
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 33
1.5.5 ASSUMPTIONS 33

2 EXECUTIVE SUMMARY 35

3 MARKET OVERVIEW 40

3.1 INTRODUCTION 41
3.2 DEFINITION OF RADIOPHARMACEUTICALS 41
3.3 MARKET SEGMENTATION 41
3.3.1 RADIOPHARMACEUTICALS 41
3.3.2 STABLE ISOTOPES 43
3.4 MARKET DYNAMICS 44
3.4.1 DRIVERS 45
3.4.1.1 Increasing incidence of cancer and cardiac ailments boosts the demand for radiopharmaceuticals 45
3.4.1.2 Increasing use of SPECT and PET scans results in rise of radiopharmaceutical usage 45
3.4.1.3 Rising awareness of radiopharmaceuticals to spur growth 46
3.4.1.4 Ready availability of radiopharmaceuticals from cyclotrons to goad the growth 46
3.4.2 RESTRAINTS 47
3.4.2.1 Shorter half-life of radiopharmaceuticals restricts the usage 47
3.4.2.2 High capital to limit the buying of scanners 47
3.4.2.3 Competition from conventional diagnostic procedures 47
3.4.3 OPPORTUNITIES 48
3.4.3.1 Potential radioisotopes in the pipeline 48
3.4.3.2 Alpha radioimmunotherapy-based targeted cancer treatment 48
3.4.3.3 Cyclotron-based production 49
3.4.3.4 Neurological applications 49
3.4.4 THREAT 50
3.4.4.1 Japanese reactors inefficient to compensate the domestic nuclear demand 50
3.5 WINNING IMPERATIVES 50
3.5.1 INVESTMENTS ON NEW RADIOISOTOPES AND NOVEL APPLICATIONS 50
3.5.2 SHIFT TOWARDS LEU-BASED MO-99 PRODUCTION 51
3.6 BURNING ISSUES 51
3.6.1 HIGH COST OF PET CAMERAS 51
3.6.2 FUKUSHIMA NUCLEAR DISASTER 51
3.7 OPAL - A SUSTAINABLE SOLUTION FOR GLOBAL CRISIS IN MO-99 SUPPLY 52
3.8 REGULATORY AFFAIRS 52
3.8.1 JAPAN 52
3.8.1.1 The Pharmaceuticals and Medical Devices Agency (PMDA, SOGO-KIKO) 52
3.8.2 CHINA 53
3.8.2.1 China Food and Drug Administration (CFDA) and Office of Administrative Protection for Pharmaceuticals (OAPP) 53
3.8.3 INDIA 53
3.8.3.1 Board of Radiation and Isotope Technology (BRIT) 53
3.8.4 SOUTH KOREA 54
3.8.4.1 Korea Institute of Nuclear Safety (KINS) and Korea Institute of Nuclear Nonproliferation and Control (KINAC) 54
3.8.5 MALAYSIA 54
3.8.5.1 Atomic Energy Licensing Board (AELB) 54
3.8.6 INDONESIA 55
3.8.6.1 Nuclear Energy Regulatory Agency (BAPETEN) 55
3.8.7 AUSTRALIA and NEW ZEALAND 55
3.8.7.1 The Australian and New Zealand Society of Nuclear Medicine (ANZSNM) 55
3.8.8 ROA 56
3.8.8.1 DOST (Philippines) and CRPNS (Singapore) 56
3.9 MARKET SHARE ANALYSIS 57
3.9.1 RADIOPHARMACEUTICALS MARKET 57
3.9.2 ENRICHED STABLE ISOTOPE MARKET 59

4 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 61

4.1 INTRODUCTION 62
4.2 DIAGNOSTIC MARKET 62
4.2.1 OPPORTUNITY MATRIX 63
4.2.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) RADIOPHARMACEUTICALS 65
4.2.2.1 Technetium-99m (Tc-99m) 67
4.2.2.1.1 Tc-99m to decide growth trend of SPECT radioisotopes 69
4.2.2.1.2 Factors affecting Technetium-99m market 70
4.2.2.1.2.1 Technetium can combine with 31 different carrier molecules 70
4.2.2.1.2.2 Sustainable supply of technetium 71
4.2.2.2 Thallium-201 (Tl-201) 71
4.2.2.2.1 Tl-201 is a potential substitute for Tc-99m 71
4.2.2.3 Gallium-67 (Ga-67) 73
4.2.2.3.1 Fluorine-18 (PET) might seize Ga-67 (SPECT) market share in the near future 73
4.2.2.4 Iodine (I-123) 74
4.2.2.5 Others 76
4.2.3 POSITRON-EMISSION TOMOGRAPHY (PET) RADIOPHARMACEUTICALS 78
4.2.3.1 Fluorine-18 81
4.2.3.1.1 FDG 81
4.2.3.1.2 Florbetapir 81
4.2.3.1.3 Factors affecting Fluorine-18 market 83
4.2.3.1.3.1 Rise in PET procedures increases demand for FDG 83
4.2.3.1.3.2 High generation costs of FDG 83
4.2.3.1.3.3 Need for speedy and efficient transportation 83
4.2.3.2 Rubidium-82 (Rb-82) 83
4.2.3.3 Others 84
4.3 THERAPEUTIC ISOTOPES 86
4.3.1 OPPORTUNITY MATRIX 87
4.3.2 BETA EMITTERS 88
4.3.2.1 Iodine-131 (I-131) 90
4.3.2.2 Yttrium-90 (Y-90) 92
4.3.2.2.1 Y-90 market influenced by popularity of Nordion's TheraSphere 92
4.3.2.3 Samarium-153 (Sm-153) 94
4.3.2.4 Rhenium-186 (Re-186) 95
4.3.2.5 Lutetium-177 (Lu-177) 97
4.3.2.5.1 Lu-177 is a potential treatment option for neuroendocrine cancer 97
4.3.2.6 Others 98
4.3.2.6.1 Re-188 and P-33 are notable promising isotope 99
4.3.3 ALPHA EMITTERS 100
4.3.3.1 Radium-223 (Ra-223) and Alpharadin 101
4.3.3.1.1 Successful completion of Phase III trials in men with bone metastases from CRPC 102
4.3.3.1.2 First in-class alpha pharmaceutical 103
4.3.3.1.3 Alpharadin is advantageous over Taxotere, beta-therapy and brachytherapy 103
4.3.3.1.4 Success of Alpharadin 103
4.3.3.1.5 Porter's five forces analysis 104
4.3.3.1.6 SWOT analysis 105
4.3.3.2 Actinium-225 (Ac-225) 106
4.3.3.3 Lead-212 (Pb-212)/Bismuth-212 (Bi-212) 106
4.3.3.4 Astatine-211 (At-211) 106
4.3.3.5 Radium-224 (Ra-224) 106
4.3.3.6 Thorium-227 (Th-227) 106
4.3.4 BRACHYTHERAPY 107
4.3.4.1 Cesium-131 110
4.3.4.2 Iodine-125 111
4.3.4.3 Palladium-103 112
4.3.4.4 Iridium-192 114
4.3.4.5 Others 115

5 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET,
BY APPLICATION/INDICATION 117

5.1 INTRODUCTION 118
5.2 DIAGNOSTIC APPLICATION 118
5.2.1 SPECT 119
5.2.1.1 Cardiology 121
5.2.1.2 Lymphoma 122
5.2.1.3 Thyroid 124
5.2.1.4 Neurology 126
5.2.1.4.1 Alzheimer's, dementia, and Parkinson's disease driving growth of the neurology SPECT market 126
5.2.1.5 Others 127
5.2.2 PET 129
5.2.2.1 Oncology 130
5.2.2.1.1 FDG F-18 has become a gold standard for oncology diagnosis using PET scan 130
5.2.2.2 Cardiology 131
5.2.2.3 Neurology 133
5.2.2.4 Others 134
5.3 THERAPEUTIC APPLICATION 136
5.3.1 THYROID 138
5.3.2 BONE METASTASIS 139
5.3.3 LYMPHOMA 140
5.3.4 ENDOCRINE TUMORS 142
5.3.5 OTHERS 143

6 ASIA-PACIFIC ENRICHED STABLE ISOTOPES MARKET 145

6.1 INTRODUCTION 146
6.2 MARKET OVERVIEW 147
6.3 MARKET DYNAMICS 148
6.3.1 DRIVERS 148
6.3.1.1 Stable isotopes are natural in origin and hence safe 148
6.3.1.2 Proteomics and system biology, major factors to boost the growth of stables 148
6.3.1.3 Medical applications propel stable isotopes market growth 148
6.3.2 RESTRAINTS 149
6.3.2.1 Harmful effects of high doses of stable isotopes affect market growth 149
6.3.2.2 High cost of stables isotope 149
6.4 ENRICHED STABLES MARKET, BY ISOTOPE 150
6.4.1 DEUTERIUM and O-18 ARE PROMISING ISOTOPES 151
6.4.2 CARBON-13 152
6.4.3 DEUTERIUM 154
6.4.4 OXYGEN-18 155
6.4.5 NITROGEN-15 156
6.4.6 OTHER STABLE ISOTOPES 157
6.5 ENRICHED STABLES MARKET, BY APPLICATION 158
6.5.1 DIAGNOSTIC and THERAPY 159
6.5.2 RESEARCH 160
6.5.3 PHARMACEUTICAL 161
6.5.4 INDUSTRIAL SECTOR 163

7 GEOGRAPHIC ANALYSIS 165

7.1 INTRODUCTION 166
7.1.1 APAC SHOWCASES GREAT SCOPE FOR MARKET DEVELOPMENT 166
7.2 JAPAN 168
7.2.1 PET DIAGNOSIS INCREASED DRAMATICALLY AFTER 2002 168
7.2.2 JAPANESE NUCLEAR MARKET AFFECTED BY FUKUSHIMA CATASTROPHE IN 2011 168
7.3 CHINA 174
7.3.1 ALTERNATIVE PROCEDURES HINDER NUCLEAR MEDICINE MARKET 174
7.4 INDIA 180
7.4.1 TC-99M AND F-18 FDG, THE MOST PROMINENT RADIOPHARMACEUTICALS 180
7.5 SOUTH KOREA 186
7.5.1 NUCLEAR MEDICINES MARKET GAINED MOMENTUM AFTER MID-1990S 186
7.6 MALAYSIA 192
7.6.1 NUCLEAR MEDICINES MARKET SHOWCASED A SIGNIFICANT DEVELOPMENT DURING THE POST 1970'S ERA 192
7.6.2 PATIENTS MIGRATING TO NEIGHBORING COUNTRIES FOR NUCLEAR MEDICINE SERVICES 192
7.7 INDONESIA 198
7.7.1 LACK OF SKILLED PROFESSIONALS AFFECTS INDONESIAN NUCLEAR MEDICINES MARKET 198
7.8 AUSTRALIA 204
7.8.1 THE OPAL REACTOR HAS THE CAPACITY TO PRODUCE ALMOST HALF THE GLOBAL TC-99M DEMAND 204
7.8.2 UNINTERRUPTED MO-99 PRODUCTION BY OPAL TO BOOST TC-99M USAGE 204
7.9 NEW ZEALAND 210
7.9.1 ALTERNATIVE PROCEDURES AFFECT NUCLEAR MEDICINES MARKET 210
7.10 REST OF ASIA (ROA) 216

8 COMPETITIVE LANDSCAPE 222

8.1 INTRODUCTION 222
8.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS and
JOINT VENTURES 223
8.3 PRODUCTS LAUNCH 226
8.4 EXPANSIONS 227
8.5 MERGERS and ACQUISITIONS 228
8.6 OTHER DEVELOPMENTS 229

9 COMPANY PROFILES 232

9.1 BRACCO IMAGING S.P.A. 232
9.2 CAMBRIDGE ISOTOPE LABORATORIES, INC. 235
9.3 CARDINAL HEALTH, INC. 239
9.4 COVIDIEN, PLC 244
9.5 ECZACIBASI-MONROL 249
9.6 FUJIFILM HOLDINGS CORPORATION 251
9.7 GE HEALTHCARE
(SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 256
9.8 IBA GROUP 261
9.9 ISOTEC, INC. (SIGMA-ALDRICH) 267
9.10 LANTHEUS MEDICAL IMAGING, INC. 271
9.11 NORDION, INC. 278
9.12 NTP RADIOISOTOPES (PTY), LTD. 284
9.13 SIEMENS HEALTHCARE (SUBSIDIARY OF SIEMENS AG) 287
9.14 TAIYO NIPPON SANSO CORPORATION 292
9.15 URENCO LIMITED 296
9.16 ROTEM INDUSTRIES, LTD., INC. 299
9.17 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO) 301
9.18 BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT) 305
9.19 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE 307
9.20 INSTITUTE OF ISOTOPES CO., LTD. 309
9.21 INSTITUTE OF RADIOELEMENT (IRE) 312
*Details On Financials, Products and Services, Key Strategy, and Recent Developments Might Not Be Captured In Case Of Unlisted Companies.

LIST OF TABLES

TABLE 1 ASIA-PACIFIC: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET,
BY TECHNOLOGY, 2010 - 2017 ($MILLION) 36
TABLE 2 ASIA-PACIFIC: RADIOPHARMACEUTICAL DIAGNOSTIC MARKET,
BY TECHNOLOGY, 2010 - 2017 ($MILLION) 63
TABLE 3 ASIA-PACIFIC: SPECT RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2010 - 2017 ($MILLION) 66
TABLE 4 ASIA-PACIFIC: SPECT RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 67
TABLE 5 INDICATIONS DIAGNOSED BY TC-99M 68
TABLE 6 ASIA-PACIFIC: TC-99M MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 70
TABLE 7 ASIA-PACIFIC: TL-201 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 72
TABLE 8 ASIA-PACIFIC: GA-67 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 74
TABLE 9 ASIA-PACIFIC: I-123 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 75
TABLE 10 ASIA-PACIFIC: OTHER RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 77
TABLE 11 ASIA-PACIFIC: PET RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2010 - 2017 ($MILLION) 79
TABLE 12 ASIA-PACIFIC: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 80
TABLE 13 ASIA-PACIFIC: F-18 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 82
TABLE 14 ASIA-PACIFIC: RB-82 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 84
TABLE 15 ASIA-PACIFIC: OTHER PET RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 85
TABLE 16 ASIA-PACIFIC: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 - 2017 ($MILLION) 86
TABLE 17 ASIA-PACIFIC: BETA EMITTER RADIOPHARMACEUTICALS MARKET,
BY ISOTOPE, 2010 - 2017 ($MILLION) 89
TABLE 18 ASIA-PACIFIC: BETA EMITTER RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 - 2017 ($MILLION) 90
TABLE 19 ASIA-PACIFIC: I-131 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 91
TABLE 20 ASIA-PACIFIC: Y-90 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 93
TABLE 21 ASIA-PACIFIC: SM-153 MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 95
TABLE 22 ASIA-PACIFIC: RE-186 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 96
TABLE 23 ASIA-PACIFIC: LU-177 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 98
TABLE 24 ASIA-PACIFIC: OTHER BETA EMITTERS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 99
TABLE 25 ALPHA EMITTERS VS BETA EMITTERS 100
TABLE 26 RADIOPHARMACEUTICALS CHARACTERISTICS and DOSE DELIVERY OVER TIME 107
TABLE 27 ASIA-PACIFIC: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 109
TABLE 28 ASIA-PACIFIC: BRACHYTHERAPY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 110
TABLE 29 ASIA-PACIFIC: CS-131 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 111
TABLE 30 ASIA-PACIFIC: I-125 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 112
TABLE 31 ASIA-PACIFIC: PD-103 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 113
TABLE 32 ASIA-PACIFIC: IR-192 MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 114
TABLE 33 ASIA-PACIFIC: OTHER BRACHYTHERAPY MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 115
TABLE 34 ASIA-PACIFIC: SPECT APPLICATION MARKET, 2010 - 2017 ($MILLION) 120
TABLE 35 ASIA-PACIFIC: CARDIOLOGY SPECT MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 121
TABLE 36 ASIA-PACIFIC: LYMPHOMA SPECT MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 123
TABLE 37 ASIA-PACIFIC: THYROID SPECT MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 125
TABLE 38 ASIA-PACIFIC: NEUROLOGY SPECT MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 127
TABLE 39 ASIA-PACIFIC: OTHER SPECT APPLICATIONS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 128
TABLE 40 ASIA-PACIFIC: PET APPLICATION MARKET, 2010 - 2017 ($MILLION) 129
TABLE 41 ASIA-PACIFIC: ONCOLOGY PET MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 131
TABLE 42 ASIA-PACIFIC: CARDIOLOGY PET MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 132
TABLE 43 ASIA-PACIFIC: NEUROLOGY PET MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 134
TABLE 44 ASIA-PACIFIC: OTHER PET APPLICATIONS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 135
TABLE 45 ASIA-PACIFIC: RADIOPHARMACEUTICAL THERAPEUTIC APPLICATION MARKET, 2010 - 2017 ($MILLION) 136
TABLE 46 ASIA-PACIFIC: RADIOPHARMACEUTICAL THERAPEUTIC APPLICATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 137
TABLE 47 ASIA-PACIFIC: RADIOPHARMACEUTICAL THYROID APPLICATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 138
TABLE 48 ASIA-PACIFIC: RADIOPHARMACEUTICAL BONE METASTASIS APPLICATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 140
TABLE 49 ASIA-PACIFIC: RADIOPHARMACEUTICAL LYMPHOMA APPLICATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 141
TABLE 50 ASIA-PACIFIC: RADIOPHARMACEUTICAL ENDOCRINE APPLICATION MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 143
TABLE 51 ASIA-PACIFIC: RADIOPHARMACEUTICAL OTHER APPLICATIONS MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 144
TABLE 52 ASIA-PACIFIC: STABLE ISOTOPE MARKET, 2010 - 2017 ($MILLION) 150
TABLE 53 ASIA-PACIFIC: STABLE ISOTOPE MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 152
TABLE 54 ASIA-PACIFIC: CARBON STABLE ISOTOPE MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 153
TABLE 55 ASIA-PACIFIC: DEUTERIUM STABLE ISOTOPE MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 154
TABLE 56 ASIA-PACIFIC: OXYGEN STABLE ISOTOPE MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 155
TABLE 57 ASIA-PACIFIC: NITROGEN STABLE ISOTOPE MARKET, BY COUNTRY, 2010 - 2017 ($MILLION) 156
TABLE 58 ASIA-PACIFIC: OTHER STABLE ISOTOPE MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 157
TABLE 59 ASIA-PACIFIC: ENRICHED STABLE ISOTOPE MARKET, BY APPLICATION, 2010 - 2017 ($MILLION) 158
TABLE 60 ASIA-PACIFIC: STABLE ISOTOPES MARKET FOR DIAGNOSTIC and THERAPEUTIC APPLICATIONS, BY COUNTRY, 2010 - 2017 ($MILLION) 159
TABLE 61 ASIA-PACIFIC: STABLE ISOTOPES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2010 - 2017 ($MILLION) 161
TABLE 62 ASIA-PACIFIC: STABLE ISOTOPES MARKET FOR PHARMACEUTICAL APPLICATIONS, BY COUNTRY, 2010 - 2017 ($MILLION) 162
TABLE 63 ASIA-PACIFIC: STABLE ISOTOPES MARKET FOR INDUSTRIAL APPLICATIONS, BY COUNTRY, 2010 - 2017 ($MILLION) 163
TABLE 64 ASIA-PACIFIC: RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2010 - 2017 ($MILLION) 167
TABLE 65 JAPAN: SPECT RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 169
TABLE 66 JAPAN: PET RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 170
TABLE 67 JAPAN: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 - 2017 ($MILLION) 170
TABLE 68 JAPAN: BETA EMITTER MARKET, BY ISOTOPE, 2010 - 2017 ($MILLION) 171
TABLE 69 JAPAN: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 172
TABLE 70 JAPAN: STABLE ISOTOPE MARKET, 2010 - 2017 ($MILLION) 173
TABLE 71 CHINA: SPECT RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 175
TABLE 72 CHINA: PET RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 176
TABLE 73 CHINA: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 - 2017 ($MILLION) 176
TABLE 74 CHINA: BETA EMITTER MARKET, BY ISOTOPE, 2010 - 2017 ($MILLION) 177
TABLE 75 CHINA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 178
TABLE 76 CHINA: STABLE ISOTOPE MARKET, 2010 - 2017 ($MILLION) 179
TABLE 77 INDIA: SPECT RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 181
TABLE 78 INDIA: PET RADIOPHARMACEUTICAL MARKET, 2010 - 2017 ($MILLION) 182
TABLE 79 INDIA: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 - 2017 ($MILLION) 182
TABLE 80 INDIA: BETA EMITTER MARKET, BY ISOTOPE, 2010 - 2017 ($MILLION) 183
TABLE 81 INDIA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 184
TABLE 82 INDIA: STABLE ISOTOPE MARKET, 2010 - 2017 ($MILLION) 185
TABLE 83 S. KOREA: SPECT RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 187
TABLE 84 S. KOREA: PET RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 188
TABLE 85 S. KOREA: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 - 2017 ($MILLION) 188
TABLE 86 S. KOREA: BETA EMITTER MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 189
TABLE 87 S. KOREA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 190
TABLE 88 S. KOREA: STABLE ISOTOPE MARKET, 2010 - 2017 ($MILLION) 191
TABLE 89 MALAYSIA: SPECT RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 193
TABLE 90 MALAYSIA: PET RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 194
TABLE 91 MALAYSIA: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 - 2017 ($MILLION) 194
TABLE 92 MALAYSIA: BETA EMITTER MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 195
TABLE 93 MALAYSIA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 196
TABLE 94 MALAYSIA: STABLE ISOTOPE MARKET, 2010 - 2017 ($MILLION) 197
TABLE 95 INDONESIA: SPECT RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 199
TABLE 96 INDONESIA: PET RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 200
TABLE 97 INDONESIA: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 - 2017 ($MILLION) 200
TABLE 98 INDONESIA: BETA EMITTER MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 201
TABLE 99 INDONESIA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 202
TABLE 100 INDONESIA: STABLE ISOTOPE MARKET, 2010 - 2017 ($MILLION) 203
TABLE 101 AUSTRALIA: SPECT RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 205
TABLE 102 AUSTRALIA: PET RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 206
TABLE 103 AUSTRALIA: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 - 2017 ($MILLION) 206
TABLE 104 AUSTRALIA: BETA EMITTER MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 207
TABLE 105 AUSTRALIA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 208
TABLE 106 AUSTRALIA: STABLE ISOTOPE MARKET, 2010 - 2017 ($MILLION) 209
TABLE 107 NEW ZEALAND: SPECT RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 211
TABLE 108 NEW ZEALAND: PET RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 212
TABLE 109 NEW ZEALAND: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 - 2017 ($MILLION) 212
TABLE 110 NEW ZEALAND: BETA EMITTER MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 213
TABLE 111 NEW ZEALAND: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 - 2017 ($MILLION) 214
TABLE 112 NEW ZEALAND: STABLE ISOTOPE MARKET, 2010 - 2017 ($MILLION) 215
TABLE 113 ROA: SPECT RADIOPHARMACEUTICAL MARKET,
2010 - 2017 ($MILLION) 217
TABLE 114 ROA: PET RADIOPHARMACEUTICAL MARKET, 2010 - 2017 ($MILLION) 218
TABLE 115 ROA: RADIOPHARMACEUTICAL MARKET, BY THERAPY,
2010 - 2017 ($MILLION) 218
TABLE 116 ROA: BETA EMITTER MARKET, BY ISOTOPE, 2010 - 2017 ($MILLION) 219
TABLE 117 ROA: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 - 2017 ($MILLION) 220
TABLE 118 ROA: STABLE ISOTOPE MARKET, 2010 - 2017 ($MILLION) 221
TABLE 119 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS and JOINT VENTURES, 2010 - 2013 223
TABLE 120 PRODUCTS LAUNCH, 2010 - 2013 226
TABLE 121 EXPANSIONS, 2010 - 2012 227
TABLE 122 MERGERS and ACQUISITIONS, 2010 - 2012 228
TABLE 123 OTHER DEVELOPMENTS, 2010 - 2012 229
TABLE 124 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,
BY SEGMENT, 2010 - 2012 ($MILLION) 236
TABLE 125 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,
BY GEOGRAPHY, 2010 - 2012 ($MILLION) 237
TABLE 126 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 240
TABLE 127 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($MILLION) 241
TABLE 128 COVIDIEN, PLC: TOTAL REVENUE AND RandD EXPENDITURE,
2010 - 2012 ($MILLION) 245
TABLE 129 COVIDIEN, PLC: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 245
TABLE 130 COVIDIEN, PLC: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($MILLION) 246
TABLE 131 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 253
TABLE 132 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($MILLION) 253
TABLE 133 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND RandD EXPENSES, 2009 - 2011 ($BILLION) 257
TABLE 134 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENT,
2009 - 2011 ($BILLION) 258
TABLE 135 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY,
2009 - 2011 ($BILLION) 258
TABLE 136 IBA GROUP: MARKET REVENUE, BY SEGMENT, 2009 - 2011 ($MILLION) 262
TABLE 137 IBA GROUP: TOTAL REVENUE, BY GEOGRAPHY,
2009 - 2011 ($MILLION) 263
TABLE 138 ISOTEC INC.: TOTAL REVENUE, BY SEGMENT, 2009 - 2011 ($MILLION) 268
TABLE 139 ISOTEC INC.: TOTAL REVENUE, BY GEOGRAPHY,
2009 - 2011 ($MILLION) 269
TABLE 140 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 - 2011 ($MILLION) 273
TABLE 141 LANTHEUS: TOTAL REVENUE, BY GEOGRAPHY, 2009 - 2011 ($MILLION) 273
TABLE 142 NORDION, INC.: TOTAL REVENUE, BY SEGMENT,
2010 - 2012 ($MILLION) 280
TABLE 143 SIEMENS AG: TOTAL REVENUE AND RandD EXPENSES,
2010 - 2012 ($MILLION) 288
TABLE 144 SIEMENS AG: TOTAL REVENUE, BY SEGMENT, 2010 - 2012 ($MILLION) 288
TABLE 145 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($MILLION) 289
TABLE 146 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE, BY GEOGRAPHY,
2010 - 2012 ($MILLION) 294

LIST OF FIGURES

FIGURE 1 ASIA-PACIFIC: RADIOPHARMACEUTICALS MARKET, BY SEGMENT,
2010 - 2017 36
FIGURE 2 ASIA-PACIFIC: RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2012 37
FIGURE 3 ASIA-PACIFIC: STABLE ISOTOPES MARKET, 2012 - 2017 ($MILLION) 38
FIGURE 4 RADIOPHARMACEUTICALS MARKET SEGMENTATION 42
FIGURE 5 ENRICHED STABLE ISOTOPES MARKET SEGMENTATION 43
FIGURE 6 MARKET DYNAMICS 44
FIGURE 7 ASIA-PACIFIC: RADIOPHARMACEUTICALS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2012 57
FIGURE 8 ASIA-PACIFIC: ENRICHED STABLE ISOTOPE MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2012 60
FIGURE 9 OPPORTUNITY MATRIX: ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS MARKET, 2012 64
FIGURE 10 SPECT RADIOPHARMACEUTICALS MARKET SHARE, 2012 65
FIGURE 11 PET RADIOPHARMACEUTICALS MARKET SHARE, 2012 78
FIGURE 12 OPPORTUNITY MATRIX: ASIA-PACIFIC THERAPEUTIC RADIOPHARMACEUTICALS MARKET, 2012 87
FIGURE 13 RA-223 DECAY CHAIN 102
FIGURE 14 PORTER'S FIVE FORCES ANALYSIS FOR ALPHARADIN 104
FIGURE 15 SWOT ANALYSIS OF ALPHARADIN 105
FIGURE 16 ASIA-PACIFIC: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY INDICATION, 2012 119
FIGURE 17 KEY GROWTH STRATEGIES, 2010 - 2013 222
FIGURE 18 CAMBRIDGE ISOTOPE LABORATORIES, INC.: TOTAL REVENUE AND RandD EXPENSES, 2010 - 2012 ($BILLION) 236
FIGURE 19 CARDINAL HEALTH, INC.: TOTAL REVENUE, 2010 - 2012 ($BILLION) 240
FIGURE 20 COVIDIEN, PLC: RADIOPHARMACEUTICALS REVENUE,
2010 - 2012 ($BILLION) 246
FIGURE 21 FUJIFILM HOLDINGS CORP: TOTAL REVENUE AND RandD EXPENDITURE, 2010 - 2012 ($BILLION) 252
FIGURE 22 IBA GROUP: TOTAL MARKET REVENUE, 2009 - 2011 ($MILLION) 262
FIGURE 23 ISOTEC INC.: TOTAL REVENUE AND RandD EXPENSES,
2009 - 2011 ($BILLION) 268
FIGURE 24 LANTHEUS: TOTAL REVENUE AND RandD EXPENSES,
2009 - 2011 ($MILLION) 272
FIGURE 25 NORDION, INC.: TOTAL MARKET REVENUE, 2010 - 2012 ($BILLION) 279
FIGURE 26 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE AND RandD EXPENDITURE, 2010 - 2012 ($BILLION) 293
FIGURE 27 URENCO LIMITED: TOTAL MARKET REVENUE, 2009 - 2011 ($BILLION) 297

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the ...

Global Nuclear Medicine Market

Global Nuclear Medicine Market

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global nuclear medicines market is expected to reach USD 17,600 million by the end of 2020, growing at a CAGR of around 12.29% from 2015 to 2020. Nuclear medicine utilizes the radioisotope for application ...

Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2016 Market Research Report

Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global European ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.